We are live on
!
Find out more
GCM
Gladius Capital Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
25.75%
This Fund
S&P 500
This Quarter
Est. Return
+6.29%
1 Year Est. Return
+25.75%
3 Year Est. Return
+78.03%
5 Year Est. Return
+67.88%
10 Year Est. Return
+218.88%
AUM
$1.72B
AUM Growth
+$325M
(+23%)
Cap. Flow
+$219M
Cap. Flow
% of AUM
12.75%
Top 10 Holdings %
Top 10 Hldgs %
55.41%
Holding
448
New
102
Increased
117
Reduced
145
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$89.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$15.7M |
| 3 |
JPMorgan Chase
JPM
|
+$6.39M |
| 4 |
Bank of America
BAC
|
+$4.74M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$3.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$34.1M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$28.3M |
| 3 |
UnitedHealth
UNH
|
+$20.4M |
| 4 |
NVIDIA
NVDA
|
+$20.2M |
| 5 |
Walmart Inc
WMT
|
+$10.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 1.29% |
| 2 | Healthcare | 1.06% |
| 3 | Consumer Staples | 0.73% |
| 4 | Technology | 0.61% |
| 5 | Consumer Discretionary | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Century Therapeutics
IPSC
$343M
| $26.8K | ﹤0.01% |
+7,730
| New | +$33.9K |
|
|
BCOV
302
DELISTED
Brightcove, Inc.
BCOV
| $26.5K | ﹤0.01% |
5,955
-852
| -13% | -$4.76K |
|
303
Unisys
UIS
$210M
| $26K | ﹤0.01% |
6,700
-5,328
| -44% | -$25.7K |
|
304
Lyell Immunopharma
LYEL
$348M
| $26K | ﹤0.01% |
+550
| New | +$29.4K |
|
305
Celularity
CELU
$19.8M
| $25.9K | ﹤0.01% |
+4,184
| New | +$33.7K |
|
306
Atea Pharmaceuticals
AVIR
$399M
| $25.8K | ﹤0.01% |
7,713
-200
| -3% | -$811 |
|
307
Arteris
AIP
$1.46B
| $25.7K | ﹤0.01% |
+6,066
| New | +$31.7K |
|
|
ICPT
308
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $25.5K | ﹤0.01% |
1,899
-666
| -26% | -$11.5K |
|
309
AbCellera Biologics
ABCL
$1.99B
| $25.3K | ﹤0.01% |
+3,361
| New | +$30.5K |
|
|
TPC
310
Tutor Perini Cor
TPC
$5.03B
| $25.3K | ﹤0.01% |
+4,094
| New | +$32.9K |
|
311
Caesarstone
CSTE
$76.1M
| $24.7K | ﹤0.01% |
5,970
-108
| -2% | -$599 |
|
312
Elanco Animal Health
ELAN
$12.1B
| $24.6K | ﹤0.01% |
2,616
-289
| -10% | -$3.41K |
|
313
DHI Group
DHX
$179M
| $24.1K | ﹤0.01% |
6,221
-385
| -6% | -$1.83K |
|
314
Nuvation Bio
NUVB
$2.15B
| $23.7K | ﹤0.01% |
14,302
-5,177
| -27% | -$10.5K |
|
315
Nkarta
NKTX
$164M
| $23.7K | ﹤0.01% |
6,668
+2,114
| +46% | +$10K |
|
|
ITOS
316
DELISTED
iTeos Therapeutics
ITOS
| $23.4K | ﹤0.01% |
1,716
-119
| -6% | -$2.13K |
|
317
Battalion Oil
BATL
$29.7M
| $23.3K | ﹤0.01% |
3,540
+184
| +5% | +$1.71K |
|
|
PFSW
318
DELISTED
PFSweb, Inc.
PFSW
| $22.7K | ﹤0.01% |
+5,365
| New | +$33.2K |
|
|
LONA
319
LeonaBio Inc
LONA
$73.4M
| $21.3K | ﹤0.01% |
853
-327
| -28% | -$10.5K |
|
320
Bioventus
BVS
$1.18B
| $20K | ﹤0.01% |
18,701
+262
| +1% | +$501 |
|
321
Motorcar Parts of America
MPAA
$257M
| $19K | ﹤0.01% |
2,552
-774
| -23% | -$9.22K |
|
322
Brookfield Infrastructure
BIPC
$4.87B
| $16.7K | ﹤0.01% |
363
+7
| +2% | +$305 |
|
323
American Public Education
APEI
$931M
| $16.7K | ﹤0.01% |
3,075
+253
| +9% | +$2.65K |
|
324
Universal Electronics
UEIC
$60.6M
| $16.4K | ﹤0.01% |
1,619
-62
| -4% | -$1.08K |
|
325
Otter Tail
OTTR
$3.91B
| $16.2K | ﹤0.01% |
224
-60
| -21% | -$3.99K |
|
Similar funds
ACM
BFPW
RIA
GACM
GA
LIA
GWM
Gladius Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Gladius Capital Management held 448 positions worth $1.72B, up 23% from $1.39B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Gladius Capital Management deployed $219M of net new capital in Q1 2023, opening 102 new positions and adding to 117 existing holdings. Its largest new stake was Invesco QQQ Trust: 53,172 shares worth $17.1M.
By sector, the portfolio is most concentrated in Financials at 1.3% of assets, up from 0.78% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was iShares MSCI Emerging Markets ETF, an estimated $28.3M trimmed.
- Gladius Capital Management's largest Q1 2023 buy was Invesco QQQ Trust: 53,172 shares worth $17.1M.
- Gladius Capital Management added most to State Street SPDR S&P 500 ETF Trust in Q1 2023, an estimated $89.1M increase.
- Gladius Capital Management's biggest Q1 2023 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $28.3M.
- Gladius Capital Management fully exited Apple in Q1 2023, selling an estimated $34.1M.
- Gladius Capital Management's ten largest holdings make up 55% of its $1.72B portfolio in Q1 2023.
- Gladius Capital Management opened 102 new positions and closed 81 in Q1 2023.
- Gladius Capital Management's portfolio value rose 23% quarter-over-quarter to $1.72B.
Based on Gladius Capital Management's 13F filing for Q1 2023, filed 9 May 2023.